1	AMU: Using mRNA Embedding in Self-Attention Network to Predict
2	Melanoma Immune Checkpoint Inhibitor Response
3	
4	Authors: Yi Yin ¹ , Qing Wu ² , Ziming Wang ² , Yu Kang ³ , Xianhe Xie ² *
5	Affiliations:
6	¹ Department of Medical Oncology, Clinical Oncology School of Fujian Medical University,
7	Fujian Cancer Hospital; Fuzhou, 350014, China;
8	² Department of Oncology, Molecular Oncology Research Institute, Fujian Key Laboratory of
9	Precision Medicine for Cancer, The First Affiliated Hospital of Fujian Medical University;
10	Fuzhou, 350005, China;
11	³ School of Information and Communication Engineering, Beijing University of Posts and
12	Telecommunications, Beijing, 100876, China.
13	Emails:
14	Yi Yin: elovf1@ fjmu.edu.cn
15	Qing Wu: wuqing@fjmu.edu.cn
16	Ziming Wang: wzmyx20@163.com
17	Yu Kang : ky@bupt.edu.cn
18	*Corresponding author. Email: xiexianhe@fjmu.edu.cn
19	Word count: 3020

20	Keywords: deep learning, transformer, self-attention, immunotherapy, representation learning
21	Declarations
22	Ethics statements and Patient consent for publication: Not applicable.
23	Availability of data and material: All data and codes are available in
24	https://aistudio.baidu.com/aistudio/projectdetail/4298990
25	Competing interests: Authors declare that they have no competing interests.
26	Funding: No funding
27	Author contributions:
28	Conceptualization: Yi Yin
29	Methodology: Yi Yin
30	Visualization: Yi Yin, Ziming Wang
31	Project administration: Yi Yin, Xianhe Xie, Yu Kang,
32	Supervision: Xianhe Xie, Yu Kang
33	Writing – original draft: Yi Yin
34	Writing – review & editing: Yi Yin, Qin Wu, Ziming Wang, Xianhe Xie
35	Acknowledgments: The authors thank Xiaohua Zhang, Cunxi Li for helpful discussion,
36	Tianxuan Qi for coding enlightenment, Muqun He, Jianfeng Wang and Yunjian Huang
37	for the work incentives, and thanks to Baidu Paddle team for providing free online GPU
38	and training courses to us.
39	

- **List of Abbreviations** AI: Artificial Intelligence AUC: The Area Under the Curve

- 43 CV: Computer Vision
- 44 CNN: Convolutional Neural Network
- 45 DL: Deep Learning
- 46 GNN: Graph Neural Network
- 47 GO: Gene Ontology
- 48 ICI: Immune Checkpoint Inhibitor
- 49 mAP: mean Average Precision
- 50 NLP: Natural Language Processing
- 51 ORR: Objective Response Rate
- 52 PR: Precision-Recall
- 53 ROC: receiver operating characteristic curve
- 54 SVM: Support Vector Machine
- 55 SHAP: SHapley Additive Explanations
- 56 TMB: Tumor Mutation Burden
- 57 XGBoost: eXtreme Gradient Boosting
- 58
- 59 Abstract:

60 **Background**: To precisely predict drug response and avoid unnecessary treatment have been

⁶¹ urgent needs to be resolved in the age of melanoma immunotherapy. Deep learning model is a

62 powerful instrument to predict drug response. Simultaneously extracting the function and

expression data characteristics of mRNA may help to improve the prediction performance of the

64 model. Methods: We designed a deep learning model named AMU with self-attention structure

65 which were fed with the mRNA expression values for predicting melanoma immune checkpoint

66 inhibitor clinical responses. **Results:** Comparing with SVM, Random Forest, AdaBoost,

67 XGBoost and the classic convolutional network, AMU showed the preferred performance with

the AUC of 0.941 and mAP of 0.960 in validation dataset and AUC of 0.672, mAP of 0.800 in

69 testing dataset, respectively. In model interpretation work, TNF-TNFRSF1A pathway were

- ⁷⁰ indicated as a key pathway to influence melanoma immunotherapy responses. Further, gene
- 71 features extracted from embedding layer and calculated by t-SNE algorithm, showed a local
- similarity with Functional Protein Association Network (STRING, https://cn.string-db.org/), AMU

could predict gene functions and interactions simultaneously. Conclusions: Deep learning model
built with self-attention structure has strong power to process mRNA expression data and gene
vector representation is a promising work in biomedical field.

76

77 What is already known on this topic

The types of biomarkers for immunotherapy are very complex and transcriptomics biomarker research is one part of it, but currently it is lack of generally acknowledged results with practical value. Combining deep learning models with transcriptomics biomarker markers can help us to predict drug sensitivity. However, the powerful capabilities of deep learning models have not been fully exploited and utilized.

83 What this study adds

The expression of 160 genes could well predict the efficacy of immunotherapy, even if the tissue samples were after drug administration, and through model training, we could also extract the interactions and connections between genes. The deep learning model could not only do prediction, but were also promising in performing gene vector representation learning.

88 How this study might affect research, practice or policy

Our research is not only to provide a model with high predictive value, but also to extract gene interaction relations during model training, which is very enlightening for gene vector representation learning. The research of gene vector representation learning can promote the prediction accuracy of deep learning models in various biomedical fields because it can become the common upstream of many biomedical tasks.

95 BACKGROUND

The publication of Alexnet in 2012 brought neural network back to researchers' 96 97 attention,[1]. After ten years of development, Deep learning (DL), a computer science and technology with the neural network as the core, has become one of the most active scientific 98 research fields and the primary technology of artificial intelligence. It takes a big step forward in 99 100 the development of artificial intelligence (AI), and promotes great changes and progress in the 101 fields of industry, agriculture, commerce, economic finance, and medical area etc. Deep learning-centered artificial intelligence has become a key technology in the new industrial 102 103 revolution.

DL has developed rapidly in image recognition and image segmentation, and has already 104 been mature and widely used in industry. In the field of Natural Language Processing (NLP), the 105 self-attention mechanism was proposed by Google in its famous paper "Attention is All Your 106 Need" in 2017, which is conducive to integrate the internal association between the input long 107 108 sequence data and improve the predictive accuracy of the downstream tasks such as automatic speech recognition, machine translation etc. Subsequently, the transformer network with self-109 attention mechanism as the core architecture was widely proved to be superior and quickly 110 111 became one of the acknowledged optimal basic networks. Then the transformer was transplanted to computer vision (CV) field and models such as ViT and Swin Transformer were proposed, [2, 112 3], which greatly improved the prediction accuracy of CV tasks. In the medical field, CV model 113 or NLP model with transformer is also widely used, [4], AI assisted pathological/imaging 114 diagnosis and medical data extraction are under accelerated development, [5]. Meanwhile, in the 115 field of scientific research, Graph neural network (GNN) models is often applied to drug 116 sensitivity prediction and molecule affinity prediction, [3, 6]. However, AlphaFold2 with self-117

118 attention mechanism successfully predicted protein tertiary structure based on protein primary 119 structure information last year, [7], which is believed that it can greatly improve the efficiency of protein function studies. For gene multi-omics data, most of current studies feed the data into the 120 121 Convolutional Neural Network (CNN) in the form of one hot coding or one-dimensional vector, [3, 8, 9], which seems lags behind other areas in DL domain. In this study, considering the 122 interaction and connection among genes, we tried to use transformer encoder structure with self-123 attention mechanism to manage gene expression data, which achieved good prediction results 124 and suggested the feasibility of self-attention mechanism for gene vector representation. 125 We named our DL model AMU, which meant Attention mechanism Model for predicting 126 melanoma iMMUnotherapy checkpoint inhibitor (ICI) response. In recent years, malignancy 127 immunotherapy had made great progress and significantly improved patients' overall survival, 128 especially for melanoma, immunotherapy had already acquitted as the standard treatment in the 129 advanced disease, [10, 11]. However, the clinical tumor response to immunotherapy is not 130 satisfied, and the objective response rate (ORR), which is the standard assessment criteria for 131 evaluating anti-tumor drug activation, is around 30%, [12], in some other tumors, the ORR is 132 even lower, around 10%-20%, [13, 14]. So how to precisely identify which group of patients can 133 beneficial from immunotherapy has caused much attention,[15-17]. Currently approved 134 immunotherapy treatment includes PD-1/PD-L1 inhibitor and CTLA-4 inhibitor, the biomarkers 135 for these drugs are usually PD-L1 expression level, tumor mutation burden (TMB) and MSI-136 H/dMMR status, but these biomarkers have low prediction accuracies and often contradict with 137 each other, [18-20]. The search for more precise methods has not stopped, we considered drug 138 response is related to complex biological pathways and conducted this study using muti-gene 139 140 mRNA expression values to predict ICI response.

141 We summarized our contributions follows :

142 1) In model building and developing level:

• We provided reliable evidence to reveal the superiority of our model AMU achieving excellent performance in both validation dataset and independent testing dataset for melanoma ICI response prediction, highlighting the strong predictive power and generalization ability of our model.

• We proved that the self-attention mechanism could work in 1-D vector data, even if the input data is not spatial positional type image or sequence sensitive type natural language.

• We discovered the embedding architecture could be used for representation learning of gene

150 feature and combining mRNA expression quantitative information, the interactions of

151 learned representation vector had local consistence with the widely accepted Functional

152 Protein Association Network (STRING, https://cn.string-db.org/),[21] which proved the

embedding architecture is suitable and promising for gene vector representation. Self-

154 attention mechanism was superior and benefit for digitating data inner correlation. The

interpretation of embedding layer made the DL network becoming more convincing, which

156 was especially important in biomedical area.

157 2) In biological level:

According to model interpretation work, we put forward an assumption that the TNF TNFRSF1A pathway might be a key pathway to decide melanoma ICI response.

• CD80 and CCR3 expression may related to both survival and ICI response for melanoma.

161 **METHODS**

We collected the open data to build our datasets, AMU performance was evaluated in validation and testing datasets comparing with other five machine learning models, after the model was trained, we conducted the interpretation work to explore the importance and interactions of gene functions. We used DL framework PaddlePaddle 2.3.0 to build AMU and Paddle AI Studio (<u>https://aistudio.baidu.com/aistudio/index</u>) to train model online, figures were drawn by matplotlib package.

168 **Overview of AMU framework**

AMU is constructed by a transformer encoder followed with a convolutional network for an 169 ICI clinical response binary classification task. The input data are 160 normalized mRNA 170 expression values. As the same as other classification models, the output of AMU is a pair of 171 172 probability values, which denotes non-response and response probability. The transformer encoder structure is classic as that in NLP, which will be described in detail in the following part. 173 174 In convolutional network, we used 'Convolution- Dropout - Batch Normalization - ReLU 175 activation function - Adaptive Maximum Pool' strategies. We used Adam algorithm as the 176 optimizer for back-propagation process and two-step decay of learning rate for training. AMU 177 takes the SoftMax activation function for the end of the net and cross-entropy as loss function. A 178 total of 83,462 parameters are trainable in AMU. Details see Supplement (Table S1).

179 mRNA embedding and transformer encoder layer

We set a 20-D gene embedding for gene feature learning, and the initialized embedding input is integer "1" to "160", then we multiply embedded values with mRNA expression values in order to add expression information to every embedding, this method was inspired by NLP process in which word position information is added to the embedding layer. We consider that gene features can be learned in the end-to-end training process just like words can be

representation learned in large text corpus. However, gene is not a sequence data so that the position information is not necessary and expression information should be instead. Genes have interaction and association with each other, so self-attention mechanism will be work.

188 In the process of transplanting transformer encoder layer, no structure needs to be changed,

189 which includes Layer normalization, Dropout, Muti-head attention, and Multilayer Perceptron

190 (MLP). In model training experiment, we used eight Muti-head attentions and repeated

191 transformer encoder layer eight times to avoid underfitting.

192 Building Dataset

As show in Table 5, all the cases fed into models are collected from published data, including three independent datasets GSE78220, GSE91061, GSE165278 from GEO Datasets and one dataset from the paper of Liu (PMID:31792460),[22-26]. We collected total 206 patients diagnosed with advanced melanoma treated with immunotherapy checkpoint inhibitor, including Nivolumab, Pembrolizumab and Ipilimumab. The whole-transcriptome sequencing (RNA-seq) conducted on pretreatment tumor tissues.

The testing dataset was built by 58 post-treatment tissue samples from GSE91061. Clinical information is not available in the most datasets and the patients' characteristics cannot be described. Datasets detail are shown in **Table 1**.

202

203 Table 1. Summary of datasets

	Patient		D	Sample	mRNA-seq	
Dataset ID	count	Drug applied	Biopsies type	acquisition	platform	

Training/Validation dataset (n = 206)

	GSE78220	27	Pembrolizumab	pre-anti-PD- Melanoma tissue therapy		Illumina HiSeq 2000	
	GSE91061	51	Nivolumab	Melanoma tissue	pre-anti-PD-1 therapy	Illumina Genome Analyzer	
	GSE165278	7	Ipilimumab	Melanoma tissue	pre-anti- CTLA-4 therapy	Illumina HiSeq 2500	
	Liu	121	Nivolumab/ Pembrolizumab	Melanoma tissue	pre-anti-PD-1 therapy	Illumina HiSeq 2000/ 2500	
	Testing dataset (n = 5	8)					
	GSE91061	58	Nivolumab	Melanoma tissue	post-anti-PD- 1 therapy	Illumina Genome Analyzer	
204	According to previous studies, 169 genes have been described potential associated with						
205	melanoma, inflammation, immunity, the PD-L1/CTLA4 pathways and ICI response, [27, 28, 29].						
206	Finally, 160 genes were overlapped in four datasets and selected. For response digital						
207	representation, we took records with "complete response (CR)" and "partial response (PR)" as						
208	response (classed as numeric 1), "stable disease (SD)" and "progression disease (PD)" as non-						

response (classed as numeric 0). Supplement (Data file S1) lists the full 160 gene names.

We calculated the TPM-normalized expression values by the raw data provided by authors. And continued to normalize the TPM values to constituent ratios, then we selected the 160 values from their original datasets and convert to constituent ratios again. After this step, all the values from different datasets are represent mRNA relative expression quantity and arecomparable. At last, we logarithm them.

The last, we applied up sample strategy for data enhancement, positive samples were 1:1 duplicated. A total of 280 samples were in our training/validation dataset including 148 positive samples and 132 negative samples. We randomly divided the training/ validation dataset into the training (224) and validation (56) sets, which corresponded to 80% and 20% of the total instances, respectively. In order to get reliable model performances, we randomly split training and validation data five times, which will be mentioned as "5-fold cross validation" in the following part.

222 Competing methods

We chose four machine learning models and designed one simple CNN as competing methods. All the competing models input data are 160-D vector of mRNA expression values we have been described.

• SVM (Support Vector Machine) is a first-class classification machine learning model. We employed the grid search strategy to find the optimal model hyperparameter. 'kernel' included 'linear', 'poly' and 'rbf', 'C' was in the list [1, 10, 100], 'gamma' was in the list [1, 0.1, 0.001].

• Random forest is a tree-based regressor model. We set the number of trees in the forest from range (2,10) and 'n_estimators' from arrange (10,300,10). The best hyperparameters were chosen in the comparing experiments.

•AdaBoostClassifier is a tree-based ensemble model and the best hyperparameters were
chose as the same as Random Forest.

• XGBoost (eXtreme Gradient Boosting) is a scalable tree boosting system. It implements
 machine learning algorithms under the gradient boosting framework. One of the advantages of
 XGBoostClassifier is convenience for model interpretation,[30].

• CNN, we built a simple CNN to represent traditional DL model without self-attention
mechanism. The model included three Conv1D layers and total 737 trainable parameters. Details
see Supplement (Table S2).

240 Model evaluation

In classification experiments, AUC and PR curves the two commonly used measurements were chosen as our classification metrics. To further evaluate the performance of our model, we demonstrated results under validation dataset and testing dataset respectively. We also used several common metrics in five-fold cross validations, including accuracy, precision, recall and f1 score.

246 Model interpretation

247 We selected SVM, XGBoost and AMU model to explore model interpretation works.

For SVM and XGBoost models, we applied SHAP (SHapley Additive Explanations) which is a game theoretic approach to estimate the gene feature importance, then we used GO pathway enrichment analysis and overall survival COX analysis to describe the important gene features.

For AMU model, Shap also can identify the gene importance, but more information can analysis through mRNA embedding layer. Just be inspired by NLP word embedding, we toke mRNA embedding layer 20-D trainable parameters as gene features. We tried the cluster analysis and calculated the Euclidean distance, cosine similarity and t-distributed Stochastic Neighbor Embedding (t-SNE) among gene feature vectors to describe the gene association and interaction.

256	The we compare the gene correlations with Functional Protein Interaction Network (STRING,
257	https://cn.string-db.org/) to evaluate the gene feature learned from AMU.
258	RESULTS
259	AMU accurately predicted melanoma immunotherapy response
260	We identified the performance of our model on validation and testing datasets comparing
261	with currently advanced machine learning models in five-fold cross validations. Table 2 showed
262	the binary classification reports of validation dataset predicted by original training data. DL
263	models were not preferred, and SVM had the best performance according to the accuracy score
264	(0.633) and recall score (0.633). All the models had unsatisfactory performance. XGBoost model
265	get the highest f1-score (0.567) followed by AMU (0.55), the CNN model had the lowest f1-
266	score of 0.45.

Table 2. Classification reports of Amu and five comparing methods for original validation
 dataset

The mean of five-fold cross validations	SVM	RandomForest	AdaBoost	XGBoost	CNN	AMU
Accuracy	0.633	0.608	0.531	0.618	0.620	0.590
Precision	0.512	0.471	0.435	0.553	0.500	0.560
Recall	0.633	0. 608	0.531	0.618	0.390	0.550
F1-score	0.526	0.517	0.473	0.567	0.450	0.550

270

However, after data enhancement, all the model performances were significantly improved except CNN (**Table 3**), which was hard to converge. AMU model showed the best performance with f1-score 0.93, the area under the curve (AUC) 0.941 and mean average precision (mAP) 0.960, respectively. In the testing dataset, AMU also demonstrated superior predictive perform as
show in **Table 4** and achieved the highest AUC (0.672) and mAP (0.800) respectively. The
receiver operating characteristic curve (ROC) and Precision-Recall (PR) curve were show in **Table 3. Classification reports of Amu and five comparing methods for enhanced validation**

278 dataset

The mean of five-fold cross validations	SVM	RandomForest	AdaBoost	XGBoost	CNN	AMU
Accuracy	0.884	0.653	0.821	0.792	0.544	0.930
Precision	0.906	0.707	0.872	0.854	0.524	0.930
Recall	0.892	0.654	0.821	0.792	0.534	0.930
F1-score	0.884	0.611	0.809	0.777	0.482	0.928

279

Table 4. Classification reports of Amu and five comparing methods for testing dataset

	SVM	RandomForest	AdaBoost	XGBoost	CNN	AMU
Accuracy	0.76	0.55	0.64	0.67	0.71	0.72
Precision	0.38	0.45	0.46	0.44	0.59	0.61
Recall	0.50	0.44	0.47	0.47	0.59	0.60
F1-score	0.43	0.44	0.46	0.45	0.59	0.60

281

282 Model interpretation

We listed the top-10 Shap value genes of SVM, XGBoost and AMU (**Table 5**)[31]. The top genes were quite different among models. The intersection of these top-10 genes was including

- 285 TNF and its receptor TNFRSF1A. TNF encodes a multifunctional proinflammatory cytokine.
- 286 TNFRSF1A is a member of the TNF receptor superfamily of proteins. The details of Shap values
- were in Supplementary (Fig S1-3, Data files S2-4).
- 288

Table 5. Top-10 Shap value genes prioritized by SVM, XGBoost and AMU

Module Top-10 Shap value genes	
SVM	TNFRSF1A, SERPINA1, F5, NEDD4L, TLR4, SERPINE1, GYPB, NBEA, BPGM, UBE2C
XGBoost	FASLG, CDKN1A, TP53, CD4, CASP3, HMGB1, SLC4A1, TNF, FOS, IL5
AMU	THBS1, CD86, MIF, BPGM, NRAS, TNF, IL23A, CXCL8, CD40, TNFRSF1A

290

291 Gene Ontology (GO) analysis was performed in top-50 genes of these models[32-34], total 112 genes were gathered, the enrichment analysis of pathways was show in Figure 3. The most 292 important genes are clustered in lymphocyte proliferation pathway. Then overall survival cox 293 294 analysis of these 112 genes was conducted (Figure 4), 17 genes showed statistical significance, most genes showed protect effects, only 2 genes (CD 80 and CCR3) had noteworthy hazard 295 ratios (HRs) (0.761 and 0.134 respectively). CD 80 protein was activated by the binding of CD28 296 or CTLA-4 and then induces T-cell proliferation and cytokine production. CCR3 protein is a 297 receptor for C-C type chemokines. 298 Finally, but most important, gene features learned by AMU showed biological significance. 299 We found that mRNA embedding matrix was hard to perform a desirable cluster analysis, also, 300 the Euclidean distance and cosine similarity algorithm both revealed the gene features distributed 301 302 uniformly and no aggregation. See details in Supplementary (Fig S4-7, Data file S 5-6).

- 303 However, gene association and interaction calculated with t-SNE algorithm showed locally
- 304 similar with STRING. Four cases were visualization in Figure 5. For CD4-MAPK14-PTPRC-

SOCS1 subgroup, both mRNA embedding and STRING indicated inner close association, and 305 NEDD9 relatively isolated with them. For PDE3B-ELANE-CXCL8, mRNA embedding 306 successfully mapped the close distance. In NRAS-LAGLS3-IL10-FCGR2B-CDKN1A-HMGB1 307 subgroup, most links were accurately figure out with a local difference that STRING showed 308 CDKN1A -NRAS, but mRNA embedding showed CDKN1A- FCGR2B association. Another 309 310 case was in CASP1-TLR9-CXCR3-ITGAL-TXNRD1 subgroup, most links were consistent except STRING described an interaction with CXCR3-ITGAL, but mRNA embedding didn't 311 figure it out. 312

313 **DISCUSSION**

In industrial 4.0 age, DL has been the most advanced model algorithm. Since the Alexnet 314 proposed in 2012, convolutional network renewed and a new wave of artificial intelligence 315 research and applications have begun. Then transformer has been the most advanced deep 316 learning technique and exhibited powerful performers in CV and NLP areas for its strong 317 features extraction ability of sequential and spatial interactions of data. AMU is a model 318 connected the transformer encoder with a convolutional network, it's a successful trial of proving 319 320 that the transformer structure is also feasible and superior for 1-D gene expression data (just like NLP) prediction task and splendid for gene feature learning. AMU also showed superior 321 performance in testing dataset which tissue biopsies were post ICI and some of the features and 322 323 data distribution had to be different from that of pre-ICI, further proved AMU learned some essential features. Previously, several works have been done in using mRNA expression and 324 clinical data to predict melanoma ICI response. Noam Auslander etc. reported an AUC of 0.83 325 with their IMPRES predictor, [35]. Another algorithm proposed by Philip Friedlander etc. was 326

validated in the validation set with AUCs of 0.62,[27]. By this cross-experiment comparison,
AMU exhibited its advantage.

Further, features abstracted from embedding layer showed local similarity with laboratory results or curated databases, indicating strong gene presentation abilities of transformer encoder should be fully researched and utilized for more gene related downstream tasks. DL studies should sufficiently take advantage of the power of transformer. Moreover, model interpretation is quite important for medical studies and obviously gene embedding can facilitate this work. Additionally, in the model interpretation part, SVM, XGBoost and AMU consistently

indicated that TNF- TNFRSF1A axis possess the most important genes related to melanoma ICI response process. Previous mouse experiments published in Nature showed that anti-PD-1 and anti-CTLA-4 (NIVO+IPI) combined with TNF- α inhibitors could improve the course of colitis in a mouse model and enhance the anti-tumor effect,[36]. Phase Ib clinical trial showed the promising effect of combining Nivolumab and Ipilimumab with TNF- α inhibitor in advanced melanoma,[37]. These facts indicated machine learning models not only can applied in predictive scenarios but also can provide suggestive information for further investigation.

342 Our work has several limits:

1) sample size was not large enough and the representativeness of samples was inevitably impaired, meanwhile, the patients' characteristics were not described, which will limit the extrapolation of the results. It is a common problem in medical deep learning researches because the data is limited for one specific task and unsupervised learning often works to resolve this dilemma. For DL, models have strong fitting ability, but sample diversity and distribution decide

the model generalization. A larger and closer to real situation training dataset is desired for
robust performance in most cases.

2)Although 160 genes were much less than previous studies imported 500-800 genes and more favorable for model interpretation, we consider that input features can be slimed more accurately because the ratio of input features and sample numbers should be controlled within a certain range for a better result according to Ben Sorscher's paper,[38].

354 3)A particular point we had to indicate is that, different from other fields, input features are 355 almost impossible to be enumerated in medical studies. Taking melanoma ICI response as 356 example, input data can include multi-omics, clinical, pathological and imaging data etc. Our 357 study only imported mRNA expression data, which is not complete for feature abstraction.

Looking for immunotherapy biomarkers requires multidisciplinary collaboration; our selfattention model is powerful in extraction and integration of the transcriptome information and make the drug sensitivity prediction more credible. The nature of gene is information, all kinds of advanced techniques used to process information can be tried to process gene data. In our opinion, gene representation learning work should be promising, because it can be used as a common upstream path for biological information mining and make our target tasks performed better.

365

366 **Figure 1.** The overview of AMU

Figure. 2. ROC and PR in validation dataset. (A) and (B) respectively shows ROC curve and PR curve with 6 models for validatio dataset. The PR curve shows mean average precision (mAP) of 2 classes. (C) and (D) respectively shows ROC curve and PR curve for testing dataset.

Figure 3. GO pathways enrichment analysis.

371	(A): GO results of three ontologies. (B): Biological process of pathways enrichment.
372	Figure 4. Cox analysis of Top-50 Shap value genes of (SVM, XGB, AMU) models (genes of
373	p values <0.05)
374	Figure 5. Gene interaction learned by AMU and compared with STRING
375	(A): NRAS-LAGLS3-IL10-FCGR2B-CDKN1A-HMGB
376	(B): CASP1-TLR9-CXCR3-ITGAL-TXNRD1
377	(C): PDE3B-ELANE-CXCL8
378	(D) CD4-MAPK14-PTPRC-SOCS1
379	
380	List of Supplementary Materials
381	Fig. S1: SVM Top-20 Shap gene values
382	Fig. S2: XGBoost Top-20 Shap gene values
383	Fig. S1: AMU Top-20 Shap gene values
384	Fig. S4: Clustering analysis of AMU gene embeddings
385	Fig. S5: Heatmap of Euclidean distance of AMU gene embeddings
386	Fig. S6 Heatmap of cosine similarity of AMU gene embeddings
387	Fig. S7: Bar chart of cosine similarity of AMU gene embeddings
388	Table S1: Summary of AMU framework
389	Table S2: Summary of CNN framework
390	Data files S1: 160 gene names

392	Data fi	lles S3: XGBoost Shap values				
393	Data files S4: AMU Shap values					
394	Data fi	les S5: Euclidean distance of AMU gene embeddings				
395	Data fi	les S6: cosine similarity of AMU gene embeddings				
396						
397						
398	Refer	rences				
399	1.	Krizhevsky A, Sutskever I, Hinton G E. Imagenet classification with deep convolutional neural networks.				
400		Communications of the ACM, 2017, 60(6): 84-90.				
401	2.	Dosovitskiy A, Beyer L, Kolesnikov A, et al. An image is worth 16x16 words: Transformers for image				
402		recognition at scale. arXiv preprint arXiv:2010.11929, 2020.				
403	3.	Liu Z, Lin Y, Cao Y, et al. Swin transformer: Hierarchical vision transformer using shifted				
404		windows[C]//Proceedings of the IEEE/CVF International Conference on Computer Vision. 2021: 10012-				
405		10022.				
406	4.	Devlin J, Chang M W, Lee K, et al. Bert: Pre-training of deep bidirectional transformers for language				
407		understanding. 2018. arXiv preprint arXiv:1810.04805.				
408	5.	Li J, Chen J, Tang Y, et al. Transforming medical imaging with Transformers? A comparative review of key				
409		properties, current progresses, and future perspective. 2022. arXiv preprint arXiv:2206.01136.				
410	6.	Zuo Z, Wang P, Chen X, Tian L, Ge H, Qian D. SWnet: a deep learning model for drug response prediction				
411		from cancer genomic signatures and compound chemical structures. BMC Bioinformatics. 2021;22(1):434.				
412		Published 2021 Sep 10. doi:10.1186/s12859-021-04352-9				
413	7.	Cramer P. AlphaFold2 and the future of structural biology. Nat Struct Mol Biol. 2021;28(9):704-705.				
414		doi:10.1038/s41594-021-00650-1				
415	8.	Liu Q, Hu Z, Jiang R, Zhou M. DeepCDR: a hybrid graph convolutional network for predicting cancer drug				

Data files S2: SVM Shap values

- 416 response. Bioinformatics. 2020;36(Suppl_2):i911-i918. doi:10.1093/bioinformatics/btaa822 9. 417 He D, Xie L. A Cross-Level Information Transmission Network for Hierarchical Omics Data Integration 418 and Phenotype Prediction from a New Genotype. Bioinformatics. 2021 Aug 13;38(1):204-10. doi: 419 10.1093/bioinformatics/btab580. 420 10. Dummer R, Hauschild A, Santinami M, et al. Five-Year Analysis of Adjuvant Dabrafenib plus Trametinib 421 in Stage III Melanoma. N Engl J Med. 2020;383(12):1139-1148. doi:10.1056/NEJMoa2005493 422 11. Eggermont AMM, Blank CU, Mandalà M, et al. Adjuvant pembrolizumab versus placebo in resected stage 423 III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-424 blind, randomised, controlled, phase 3 trial. Lancet Oncol. 2021;22(5):643-654. doi:10.1016/S1470-425 2045(21)00065-6-426 12. Weber JS, Gibney G, Sullivan RJ, et al. Sequential administration of nivolumab and ipilimumab with a 427 planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 428 trial [published correction appears in Lancet Oncol. 2016 Jul;17 (7):e270]. Lancet Oncol. 2016;17(7):943-429 955. doi:10.1016/S1470-2045(16)30126-7 Janjigian YY, Bendell J, Calvo E, et al. CheckMate-032 Study: Efficacy and Safety of Nivolumab and 430 13.
- 430 13. Janjigian 11, Benden J, Carvo E, et al. CheckMate-052 Study. Efficacy and Safety of Nivolumab and
 431 Nivolumab Plus Ipilimumab in Patients With Metastatic Esophagogastric Cancer [published correction
 432 appears in J Clin Oncol. 2019 Feb 10;37(5):443]. J Clin Oncol. 2018;36(28):2836-2844.
 433 doi:10.1200/JCO.2017.76.6212
- Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with
 advanced cancer. *N Engl J Med.* 2012;366(26):2455-2465. doi:10.1056/NEJMoa1200694
- Rozeman EA, Hoefsmit EP, Reijers ILM, et al. Survival and biomarker analyses from the OpACIN-neo and
 OpACIN neoadjuvant immunotherapy trials in stage III melanoma. *Nat Med.* 2021;27(2):256-263.
 doi:10.1038/s41591-020-01211-7
- 439 16. Zeng D, Wu J, Luo H, et al. Tumor microenvironment evaluation promotes precise checkpoint
 440 immunotherapy of advanced gastric cancer. *J Immunother Cancer*. 2021;9(8):e002467. doi:10.1136/jitc441 2021-002467
- 442 17. Marabelle A, Fakih M, Lopez J, et al. Association of tumour mutational burden with outcomes in patients
 443 with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the

- 444 multicohort, open-label, phase 2 KEYNOTE-158 study. *Lancet Oncol.* 2020;21(10):1353-1365.
 445 doi:10.1016/S1470-2045(20)30445-9
- Janjigian YY, Shitara K, Moehler M, et al. First-line nivolumab plus chemotherapy versus chemotherapy
 alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate
 649): a randomised, open-label, phase 3 trial. *Lancet*. 2021;398(10294):27-40. doi:10.1016/S01406736(21)00797-2
- Diaz LA Jr, Shiu KK, Kim TW, et al. Pembrolizumab versus chemotherapy for microsatellite instabilityhigh or mismatch repair-deficient metastatic colorectal cancer (KEYNOTE-177): final analysis of a
 randomised, open-label, phase 3 study. *Lancet Oncol.* 2022;23(5):659-670. doi:10.1016/S14702045(22)00197-8
- 454 20. Hellmann MD, Ciuleanu TE, Pluzanski A, et al. Nivolumab plus Ipilimumab in Lung Cancer with a High
 455 Tumor Mutational Burden. *N Engl J Med.* 2018;378(22):2093-2104. doi:10.1056/NEJMoa1801946
- Szklarczyk D, Gable AL, Nastou KC, et al. The STRING database in 2021: customizable protein-protein
 networks, and functional characterization of user-uploaded gene/measurement sets [published correction
 appears in Nucleic Acids Res. 2021 Oct 11;49(18):10800]. *Nucleic Acids Res.* 2021;49(D1):D605-D612.
 doi:10.1093/nar/gkaa1074.
- Liu D, Schilling B, Liu D, et al. Integrative molecular and clinical modeling of clinical outcomes to PD1
 blockade in patients with metastatic melanoma [published correction appears in Nat Med. 2020
 Jul;26(7):1147]. *Nat Med.* 2019;25(12):1916-1927. doi:10.1038/s41591-019-0654-5
- 463 23. Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets-464 update. *Nucleic Acids Res.* 2013;41(Database issue):D991-D995. doi:10.1093/nar/gks1193
- 465 24 Hugo W, Zaretsky JM, Sun L, et al. Genomic and Transcriptomic Features of Response to Anti-PD-1
 466 Therapy in Metastatic Melanoma [published correction appears in Cell. 2017 Jan 26;168(3):542]. *Cell*.
 467 2016;165(1):35-44. doi:10.1016/j.cell.2016.02.065
- 468 25. Zappasodi R, Serganova I, Cohen IJ, et al. CTLA-4 blockade drives loss of T_{reg} stability in glycolysis-low 469 tumours. *Nature*. 2021;591(7851):652-658. doi:10.1038/s41586-021-03326-4
- 470 26 Riaz N, Havel JJ, Makarov V, et al. Tumor and Microenvironment Evolution during Immunotherapy with
 471 Nivolumab. *Cell*. 2017;171(4):934-949.e16. doi:10.1016/j.cell.2017.09.028

- 472 27. Friedlander P, Wassmann K, Christenfeld AM, et al. Whole-blood RNA transcript-based models can predict
 473 clinical response in two large independent clinical studies of patients with advanced melanoma treated with
 474 the checkpoint inhibitor, tremelimumab. J Immunother Cancer. 2017;5(1):67. Published 2017 Aug 15.
 475 doi:10.1186/s40425-017-0272-z
- 476 28 Luo Y, Robinson S, Fujita J, et al. Transcriptome profiling of whole blood cells identifies PLEK2 and
 477 C1QB in human melanoma. *PLoS One*. 2011;6(6):e20971. doi:10.1371/journal.pone.0020971
- Saenger Y, Magidson J, Liaw B, et al. Blood mRNA expression profiling predicts survival in patients
 treated with tremelimumab. *Clin Cancer Res.* 2014;20(12):3310-3318. doi:10.1158/1078-0432.CCR-132906
- T. Chen, C. Guestrin, XGBoost: A Scalable Tree Boosting System. Proceedings of the 22nd ACM SIGKDD
 International Conference on Knowledge Discovery and Data Mining, San Francisco, 13-17 August, 2016,
 785-794. https://doi.org/10.1145/2939672.2939785
- Scott M. Lundberg, Su-In Lee. A Unified Approach to Interpreting Model Predictions. *Advances in Neural Information Processing Systems 30 (NIPS)*. 2017(30).
- 486 32. Ashburner M, Ball CA, Blake JA, et al. Gene ontology: tool for the unification of biology. The Gene
 487 Ontology Consortium. *Nat Genet*. 2000;25(1):25-29. doi:10.1038/75556.
- Mi H, Muruganujan A, Ebert D, Huang X, Thomas PD. PANTHER version 14: more genomes, a new
 PANTHER GO-slim and improvements in enrichment analysis tools. *Nucleic Acids Res.*2019;47(D1):D419-D426. doi:10.1093/nar/gky1038
- 491 34. Gene Ontology Consortium. The Gene Ontology resource: enriching a GOld mine. *Nucleic Acids Res.*492 2021;49(D1):D325-D334. doi:10.1093/nar/gkaa1113
- 493 35. Auslander N, Zhang G, Lee JS, et al. Robust prediction of response to immune checkpoint blockade
 494 therapy in metastatic melanoma [published correction appears in Nat Med. 2018 Dec;24(12):1942]. *Nat*495 *Med.* 2018;24(10):1545-1549. doi:10.1038/s41591-018-0157-9
- 496 36. Perez-Ruiz E, Minute L, Otano I, et al. Prophylactic TNF blockade uncouples efficacy and toxicity in dual
 497 CTLA-4 and PD-1 immunotherapy. *Nature*. 2019;569(7756):428-432. doi:10.1038/s41586-019-1162-y
- 498 37. Montfort A, Filleron T, Virazels M, et al. Combining Nivolumab and Ipilimumab with Infliximab or
 499 Certolizumab in Patients with Advanced Melanoma: First Results of a Phase Ib Clinical Trial. *Clin Cancer*

- 500 Res. 2021;27(4):1037-1047. doi:10.1158/1078-0432.CCR-20-3449
- 501 38. Ben Sorscher, Robert Geirhos, Shashank Shekhar, Surya Ganguli. Beyond neural scaling laws: beating power
- 502 law scaling via data pruning. 2022. arXiv:2206.14486